Unravel Biosciences

Unravel Biosciences is the first rapid prototyping therapeutics company leveraging AI models of patient RNA networks and seamless clinical validation to discover and clinically validate novel targets for neurological and non-neurological disorders, generating highly effective therapeutics. Unravel is validating a new target for Rett syndrome in the clinic while developing a new small molecule asset that has already demonstrated preclinical efficacy, a growing asset pipeline across indications, and initiating multiple therapeutics discovery partnerships.